From the free articles on MF
Edward Vesely: ResMed Inc. (CHESS) (ASX: RMD)
ResMed recently reported its financial results for the quarter ending 30 September 2016 showing revenue had increased by 13 percent. Margins were also up on the prior corresponding period, despite a fall in net income of 8.2%.
Looking forward, the company’s recent Brightree acquisition puts ResMed in a good place with double-digit earnings growth expected from its new investment in the years ahead. ResMed’s shares have fallen almost 16% from recent highs in early August, which makes this a good time to start or add to your position.
From the free articles on MF Edward Vesely: ResMed Inc. (CHESS)...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.39 |
Change
0.390(1.05%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $37.30 | $37.39 | $37.07 | $9.449M | 253.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 44 | $37.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.39 | 2573 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
